PDE5A and pulmonary arterial hypertension: Phosphodiesterases hydrolyze cGMP, and phosphodiesterase type 5 (PDE5), which is expressed especially in pulmonary vasculature and the corpus cavernosum [12], can be targeted by PDE5 inhibitors to treat erectile dysfunction and pulmonary arterial hypertension (PAH) [13,14].